FGF18 signals through fibroblast growth factor receptor FGFR3 to promote chondrogenesis and has been shown to cause thickening of cartilage in a murine model of osteoarthritis, and the recombinant version of it (sprifermin) will soon enter trials as a potential treatment for osteoarthritis